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Abstract: Selenium is an essential micronutrient for humans and animals, and is thought to 
provide protection against some forms of cancer. These protective effects appear to be 
mediated, at least in part, through selenium-containing proteins (selenoproteins). Recent 
studies in a mouse colon cancer cell line have shown that the 15 kDa selenoprotein (Sep15) 
may also play a role in promoting colon cancer. The current study investigated whether the 
effects of reversing the cancer phenotype observed when Sep15 was removed in mouse 
colon cancer cells, were recapitulated in HCT116 and HT29 human colorectal carcinoma 
cells. Targeted down-regulation of Sep15 using RNAi technology in these human colon 
cancer cell lines resulted in similarly decreased growth under anchorage-dependent and 
anchorage-independent conditions. However, the magnitude of reduction in cell growth 
was much less than in the mouse colon cancer cell line investigated previously. 
Furthermore, changes in cell cycle distribution were observed, indicating a delayed release 
of Sep15 deficient cells from the G0/G1 phase after synchronization. The potential 
mechanism by which human colon cancer cells lacking Sep15 revert their cancer 
phenotype will need to be explored further. 
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1. Introduction 
Selenium is present in the environment, and distributed widely in the Earth’s crust in varying 
concentrations, and found in trace quantities in most plant and animal tissues. While not an essential 
nutrient for plants, it is an essential nutrient for humans and many other life forms [1,2]. 
Epidemiological, clinical and preclinical studies provide evidence that selenium may protect against 
colon cancer [3–5]. Part of the protective effect appears to be mediated through selenium containing 
proteins (selenoproteins). The 15 kDa selenoprotein gene (SEP15) is one of 25 known selenoprotein 
genes in humans and 24 genes in rodents [6]. Similar to many other selenoproteins, the gene product, 
Sep15, belongs to the class of thiol-disulfide oxidoreductase—like selenoproteins [7], and has been 
shown to exhibit redox activity [8,9]. However, its mechanistic properties continue to be elucidated. In 
humans, SEP15 is located on chromosome 1p31, a locus commonly deleted or mutated in cancer [10], 
and human polymorphisms in this gene are thought to reflect differential susceptibility to cancer [11,12]. 
Other studies also suggest a role of Sep15 in cancer prevention [12,13]. 
Interestingly, more recent studies suggest that Sep15 may have an important role in promoting 
and/or sustaining colon cancer [14]. Mouse colon CT26 cells that were stably transfected with shRNA 
constructs targeting Sep15 displayed decreased growth abilities both under anchorage-dependent and 
anchorage-independent conditions. Moreover, the cells’ tumorigenic potential was decreased, as most 
mice injected with control cells had developed subcutaneous tumors, whereas few mice injected with 
Sep15-deficient cells developed tumors. The ability to form pulmonary metastases had similar results; 
i.e., mice injected intravenously with plasmid-transfected control cells developed more than 250 lung 
metastases per animal. However, mice injected with cells with down-regulation of Sep15 only formed 
7.8 ± 5.4 metastases. This influence on cellular proliferation was likely mediated, at least in part, by 
the observed G2/M cell cycle arrest in mouse colon cancer cells that lacked Sep15 expression. 
Expression of Sep15, which is regulated by dietary selenium, is found to be higher in liver, kidney, 
prostate and thryroid tissues [15,16], but can also be detected in other tissues, such as colon [17]. A 
recent study demonstrated that absence of Sep15 expression in mice in vivo does not reveal any strong 
phenotypes or gross abnormalities [16]. However, previous observations in cells [9,18,19] as well as 
these recent observations of mild oxidative stress in livers and cataract formation in lenses in Sep15 
knockout mice [16] indicate a role of Sep15 in redox homeostasis as well as glycoprotein folding. 
Knockout of Sep15 in mice in vivo has also been shown to influence colon cancer susceptibility [17]. 
The total number of carcinogen-induced aberrant crypt foci per colon and the number of aberrant 
crypts per focus were significantly lower in Sep15 knockout mice compared to wild type and 
heterozygous littermate controls. Because aberrant crypt foci serve as a surrogate biomarker for colon 
cancer risk in humans [20], these results indicate that, unlike previous observations in human 
mesothelioma cells [12], a lack of Sep15 expression may be protective against colon tumor formation 
in vivo. Nutrients 2011, 3 
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The purpose of this study was to investigate whether the effects observed when Sep15 was removed 
in mouse colon cancer cells through RNAi technology, were recapitulated in human colon cancer cells, 
for which we utilized two commercially available, p53-expressing human colorectal carcinoma cell 
lines, HCT116 and HT29. Both cell lines expressed Sep15 in appreciable levels. Our results 
demonstrate that targeted down-regulation of Sep15 in these human colon cancer cell lines indeed 
resulted in similarly decreased growth under anchorage-dependent and anchorage-independent 
conditions. However, the magnitude of the decrease in cell growth was much lower than in the mouse 
colon cancer cell line investigated previously [14], and the potential mechanism will need to be 
explored further. 
2. Experimental Section 
2.1. Materials and Reagents 
75Se (specific activity ~1000 Ci/mmol) was obtained from the Research Reactor Facility at the 
University of Missouri (Columbia, MO, USA). Dulbecco’s Minimum Essential Medium (DMEM), 
Gibco
® fetal bovine serum, puromycin, NuPage
® 4–12% polyacrylamide gels, LDS sample buffer, 
See-Blue Plus2 protein markers, and TRIzol
® reagent were purchased from Invitrogen (Carlsbad, CA, 
USA), iScript™ cDNA synthesis Kit from Bio-Rad Laboratories (Philadelphia, PA, USA), SYBR 
green supermix from New England Biolabs (Ipswich, MA, USA), primers for real-time PCR from  
Sigma-Genosys (St. Louis, MO, USA), Ribonuclease A from Sigma-Aldrich (St. Louis, MO, USA), 
and Noble agar from Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA). All other 
reagents used were commercially available and were of the highest quality available. 
2.2. Culture of Mammalian Cells and Cell Growth Assays 
HCT116 and HT29 cells were cultured in growth medium (DMEM supplemented with 10%   
heat-inactivated fetal bovine serum, 1% penicillin/streptomycin) in a humidified atmosphere with 
5% CO2 at 37 °C. Both malignant cell lines were stably transfected with shSep15 or a control construct 
as described below. Cell growth was monitored by seeding cells in 6-well plates at 1 × 10
5 cells/well in 
complete growth medium and counting cells for four days.  
2.3. Targeted Down-Regulation of Sep15 
For the generation of HCT116 shSep15 cells, two Mission
® shRNA lentiviral transduction   
particles with validated sequences were chosen for targeting Sep15 knockdown 
(CCGGCTTTGCAGCTCTTGTGATCTTCTCGAGAAGATCACAAGAGCTGCAAAGTTTTTTG or 
CCGGGAAAGGAATGACAGCAGACTACTCGAGTAGTCTCGCTGTCATTCCTTTCTTTTTTG), 
and used as described by the manufacturer (Sigma-Aldrich, St. Louis, MO, USA). Briefly, cells were 
plated at 50% confluency, and viral particles were incubated overnight following addition of 
hexadimethrine bromide. Fresh medium was applied, and HCT116 Sep15 knockdown cells were 
selected by puromycin resistance. Both sequences resulted in very similar down-regulation of Sep15, 
and only results of one construct in comparison to shRNA lentiviral control particles are reported herein.  Nutrients 2011, 3 
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For the generation of HT29 Sep15 knockdown cells, the first sequence was cloned in the pSuper 
retroviral plasmid (Oligoengine, Seattle, WA, USA) following the manufacturer’s instructions. GP-293 
cells were transfected with 1.5 µg of the retroviral vector and 1 µg of an amphotropic envelope 
expression vector (pVSV-G). Medium was changed 24 h after transfection, and cell culture 
supernatants were harvested 48 h post-transfection, filtered through a 0.22 µm filter, and diluted (1:2) 
with fresh medium. Diluted viral supernatants containing 6 µg/mL hexadimethrine bromide were then 
added to HT29 cells (plated at a low confluency 24 h prior to the infection). HT29 Sep15 knockdown 
cells were selected by puromycin resistance. 
2.4. Real-Time RT-PCR Analysis 
Total RNA was extracted from HCT116 and HT29 cells using the TRIzol
® reagent. cDNA was 
synthesized using iScript™ with 1.5 μg of total RNA. For real-time quantitative RT-PCR, 1.5 μL of 
cDNA were used in 20 μL reactions by employing the MyiQ™ Single-Color Real-Time PCR detection 
system (BioRad Laboratories, Hercules, CA, USA). Specificity of the amplifications was verified 
through analysis of the melting point curves. The primers used for real-time PCR are shown in Table 1. 
The expression of mRNA levels was calculated relative to the expression of GAPDH as the internal 
control, and was graphed relative to expression in HCT116 control cells. 
Table 1. Human real-time RT-PCR primers utilized. 
Gene Primer  Sequence 
GAPDH  5′-ACGTGTCAGTGGTGGACCTG—fwd  
5′-TGTCGCTGTTGAAGTCAGAG—rev 
GBP-1  5′-CTATGAGGAACCGAGGAAGG—fwd  
5′-CACGTTCCACTTCAATCTCC—rev  
GPx1  5′-GTGCAACCAGTTTGGGCATCS—fwd 
5′-CCGCAGGAAGGCGAAGAGAGG—rev 
GPx2  5′-CCATCAACATTGAGCCTGAC—fwd 
5′-CTAAGGCTCCTCAGGACTGG—rev 
IFN-γ  5′-TGTTACTGCCAGGACCCATA—fwd 
5′-TTCTGTCACTCTCCTCTTTCCA—rev 
SEP15  5′-CCGGCGTTTGGGCTACGGTT—fwd 
5′-CCAGCTGAAGCAGGTTGAAC—rev 
TR1  5′-CCATAGTTACTTTTGGCCAT—fwd 
5′-GCGCAGCTGCAAAGCCTTGT—rev 
2.5. 
75Se Labeling of Cells 
Cells were seeded in a six-well plate (1 × 10
5 cells/well), incubated for 18–24 h, and then labeled 
with 50 μCi/well of 
75Se for 24 h before harvesting. Cells were suspended in 1× NuPage
® LDS sample 
buffer, sonicated and 75 μg protein were electrophoresed on a NuPage
® 4–12% polyacrylamide gel. The 
gel was stained with Coomassie Blue, dried, and exposed to a PhosphorImager screen (Molecular 
Dynamics, GE Healthcare, Piscataway, NJ, USA). 
  Nutrients 2011, 3 
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2.6. Soft Agar Assay 
Anchorage-independent growth was assayed as described previously [14,21] with a total of   
3000 cells of each stably transfected cell line suspended in 3 mL of 0.35% agar in complete DMEM 
and spread onto 60 mm dishes masked with a basal layer of 3 mL of 0.7% agar in the medium. Cells 
were incubated at 37 °C, 5% CO2 for 20 days, and complete growth medium was applied to the dishes 
every 3 to 4 days. The colonies were visualized by staining with ρ-iodonitrotetrazolium violet 
overnight, scanned and counted. 
2.7. Cell Cycle Analysis 
HT29 and HCT116 cells were grown in complete medium to 60% confluency, washed twice with 
PBS, and maintained in serum-free medium for 48 h to induce G0/G1 cell cycle synchronization. Cells 
were then growth stimulated with complete growth medium for 6, 12, 24 or 48 h (n = 6). Cells were 
then washed with PBS, trypsinized and suspended in PBS (1–2 × 10
7 cells/mL) and kept on ice for  
15 min. Ice-cold 70% ethanol was added gradually and cells were fixed overnight. Cells were 
centrifuged and resuspended in Ribonuclease A (100 units) and incubated at 37 °C for 20 min. The 
suspension was stained with propidium iodide in the dark at 4 °C overnight, filtered through a   
50 micron mesh, and acquired with a FACScalibur™ (BD, Franklin Lakes, NJ, USA). The percent of 
cells in each phase of the cell cycle was analyzed by ModFit LT v.3.0 (Verity, Topsham, ME, USA). 
2.8. Statistical Analyses 
Data are presented as means ± SE and were analyzed by ANOVA or Student’s t-test using 
GraphPad Prism (v.4, LaJolla, CA, USA). Differences with P < 0.05 were considered significant. 
Levels of statistical significance were indicated as follows: * P < 0.05, ** P < 0.01, *** P < 0.001. 
3. Results 
Using RNAi-technology, Sep15 mRNA expression was reduced significantly between 85% and 95% 
in both HCT116 (P < 0.05) and HT29 (P < 0.001) colon cancer cells compared to plasmid-transfected 
controls (Figure 1a), respectively. Interestingly, HT29 cells had an over two-fold higher Sep15 mRNA 
expression (P < 0.001) compared to HCT116 cells. Other selenoproteins, including glutathione 
peroxidases 1 and 2 (GPx1 and 2), and thioredoxin reductase 1 (TR1), did not exhibit statistically 
significant differences in mRNA expression (Figure 1b–d). Subsequently, expression of Sep15 and 
other selenoproteins was visualized by labeling cells with 
75Se (Figure 2). Targeted down-regulation of 
SEP15 resulted in loss of Sep15 protein in shSep15 cells compared to the plasmid-transfected control 
cells in both HCT116 and HT29 cells. The relatively higher expression of basal Sep15 mRNA in HT29 
cells was recapitulated by the band strengths of the selenoproteins analyzed by 
75Se labeling. This may 
indicate a higher production and/or turnover rate of Sep15 in these cells. 
  Nutrients 2011, 3 
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Figure 1. mRNA expression of selenoproteins in Sep15 deficient human colorectal cancer 
cells. mRNA levels of (a) Sep15, (b) GPx1, (c) GPx2 and (d) TR1 were measured using 
quantitative real-time RT-PCR, and GAPDH was used as an internal control. Data are 
displayed as means ± SE (ANOVA, n = 3) and were graphed relative to expression in 
HCT116 control cells (cycle threshold values were 17.6, 20.1, 19.6, 29.7 and 23.5 for 
GAPDH, SEP15, GPX1, GPX2 and TR1, respectively). 
 
Figure 2. Protein expression of Sep15, GPx1/2 and TR1 upon targeted removal of Sep15 in 
HCT116 and HT29 human colorectal cancer cells, as determined by labeling cells with 
75Se.  
 Nutrients 2011, 3 
 
811
3.1. Cell Growth 
HCT116 and HT29 human colon cancer cells that lack Sep15 exhibited a significantly reduced cell 
growth as early as three days after seeding (Figure 3). The growth rate was significantly reduced, and, 
in both the HCT116 and HT29 cell lines, there were 50% (P < 0.001) and 40% (P < 0.001) fewer 
shSep15 cells after four days compared to control cells, respectively (Figure 3a,b).  
Figure 3. Effects of Sep15  deficiency on cell growth over a four day period with   
(a) HCT116 cells and (b) HT29 cells. Values are means ± SE (t-tests, n = 3–6). 
 
3.2. Anchorage-Independent Growth in Soft Agar 
The ability to grow unanchored in soft agar, which is a characteristic of many cancer cells, was also 
evaluated for both cell lines (Figure 4a–c). A representative soft agar dish with stained HT29 cell 
colonies is shown in Figure 4a. In comparison to plasmid-transfected control cells, (Figure 4b) 
HCT116 and (Figure 4c) HT29 cells transfected with the shSep15 construct had a significantly reduced 
ability to grow anchorage-independently in soft agar (P < 0.001 and P < 0.05, respectively), compared 
to the plasmid-transfected control cells. Furthermore, for both cell lines, colonies in control dishes 
appeared generally larger than those observed in dishes with shSep15 cells. Nutrients 2011, 3 
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Figure 4. Effects of Sep15 deficiency on anchorage-independent colony formation in soft 
agar as quantitated by staining cell colonies with p-iodonitrotetrazolium overnight.   
(a) Representative soft agar dishes with stained colonies of HT29 cells after 20 days; 
numbers of colonies of (b) HCT116 cells and (c) HT29 cells. Values are mean ± SE   
(t-test, n = 4).  
 
3.3. Cell Cycle Analysis 
Fluorescence-activated cell sorting (FACS) was used to evaluate whether targeted down-regulation 
of Sep15 in human colon cancer cells would result in G2/M cell cycle arrest as suggested by our 
previous results with mouse colon cancer cell lines [14]. HCT116 shSep15 cells only exhibited a very 
small, but statistically significant larger percentage of cells in the G0/G1 phase compared to controls at 
six hours past cell cycle synchronization (P < 0.01, Figure 5). However, for HT29 shSep15 cells, a 
much more pronounced statistically significant delayed release of cells from the G0/G1 phase was 
observed six hours after synchronization (Figure 5). Other time points, i.e., 12, 24 or 48 h following Nutrients 2011, 3 
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release from synchronization, did not demonstrate any marked differences between shSep15 cells and 
their respective controls (not shown). 
Figure 5. Cell cycle analysis of HCT116 and HT29 cells. Percent of cells in each phase of 
the cell cycle as determined by FACS analysis at six hours after release from synchronization 
with serum is shown. Values are means ± SE (t-tests, n = 6). 
 
3.4. Guanylate Binding Protein-1 and Interferon-γ Expression in Human Colon Cancer Cells 
Because Sep15 deficiency in mouse colon cancer cells as well as in Sep15 knockout mice in vivo 
demonstrated a highly increased expression of GBP-1 compared to controls [14,17], mRNA expression 
of GBP-1 was also evaluated in human colon cancer cells. No statistically significant increase of GBP-1 
mRNA was observed in shSep15 HCT116 or HT29 cells compared to their respective control cells 
(Figure 6a). Furthermore, mRNA expression of interferon-γ, a known inducer of GBP-1, was at the 
limit of detection and no significant differences were found between shSep15 knockdown cells and 
controls for either human cancer cell line (Figure 6b). The relatively higher levels of GBP-1 in HT29 
cells corresponded to relatively higher interferon-γ levels compared to observations in HCT116 cells. 
  Nutrients 2011, 3 
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Figure 6. mRNA expression of guanylate binding protein-1 (GBP-1) and interferon-γ 
(IFN-γ). mRNA levels of (a) GBP-1 and (b) IFN-γ  in HCT116 and HT29 colon cancer 
cells were determined by quantitative real-time RT-PCR, with GAPDH used as internal 
control. Columns depict means ± SE (t-test, n = 6), and were graphed relative to expression 
in HCT116 control cells (cycle threshold values were 17.6, 22.3 and 31.5 for GAPDH, 
GBP-1 and IFN-γ, respectively). 
 
4. Discussion 
Our previous study demonstrated that down-regulation of Sep15 may be protective against 
tumorigenesis and metastasis in murine colon cancer cells, and that these effects were mediated, at 
least in part, through an alteration of the cell cycle [14]. In the current study, we demonstrated that a 
targeted down-regulation of Sep15 in the two human colon cancer cell lines, HCT116 and HT29, also 
resulted in a reversal of the cancer phenotype. Both cell lines, upon down-regulation of Sep15, 
demonstrated significantly reduced growth abilities under both anchorage-dependent and -independent 
conditions compared to their respective controls. It appears that removing Sep15 expression may have 
protective effects against colon cancer in humans also. In contrast, as shown in our previous study, 
Sep15 deficiency had no effect on anchorage-dependent or -independent cell growth in mouse Lewis 
lung cancer cells [14]. It remains to be investigated, if this apparent tissue specificity of Sep15 
observed previously in murine cancer cells will also apply to human cancer cells. Furthermore, the 
mechanism through which Sep15 acts in human colon cancer will need to be elucidated further.  
In mouse colon cancer CT26 cells, a clear G2/M phase arrest was observed in cell cycle analysis [14], 
whereas a delayed release from G0/G1 after cell cycle synchronization was observed in human cells. Nutrients 2011, 3 
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This delayed response was especially noticeable in HT29 cells, where shSep15 cells remained in the 
G0/G1 phase significantly longer than their corresponding control cells. This observation indicates that 
a loss of Sep15 expression in at least some colon cancer cells results in an alteration of the cell cycle. 
We analyzed the mRNA expression of the interferon-γ inducible GBP-1 in both HCT116 and HT29 
cells. Our previous results had indicated that targeted removal of Sep15 in mice in vivo also induced  
a very strong up-regulation of the large GTPase GBP-1 [17], which is thought to function as an   
anti-apoptotic protein [22]. This up-regulation of GBP-1, in absence of Sep15 expression, has also 
been found in the mouse colon cancer cell line CT26 [17]. Because up-regulation of GBP-1 expression 
in humans has been associated with longer survival in colon cancer patients [23], GBP-1 is considered 
to be an activation marker of endothelial cells during inflammatory diseases. Unlike in mouse colon 
cancer CT26 cells, no statistically significant increase of GBP-1 mRNA was observed in human colon 
cancer shSep15 cells compared to their respective controls. HT29 cells, which exhibited a two-fold 
higher GBP-1 expression than HCT116 cells, and a corresponding higher interferon-γ expression, 
showed a slight increase in GBP-1 mRNA expression (P > 0.05) upon targeted down-regulation of 
Sep15 compared to their controls. Future experiments should include human (colon) cancer cell lines 
with an even higher Sep15 expression than HT29 cells, which we would anticipate to have 
significantly increased GBP-1 levels as a response to loss of Sep15.  
5. Conclusions 
Reduction of Sep15 resulted in reversal of the cancer phenotype in human colon cancer cells, with 
limited regulation through changes in cell cycle. The slight increase in GBP-1 mRNA in HT29 cells 
may reflect a stronger effect in response to loss of Sep15 in these cells. Future studies should include 
targeted down-regulation as well as over-expression of Sep15 in these and other colon cancer cell 
lines, which may be reflecting human polymorphic Sep15 status, and thus may help further elucidate 
the function of Sep15 in colon cancer in humans. Furthermore, because Sep15 expression depends on 
the selenium status, these results are important in regards to differential intake of, and response to, 
dietary selenium and potential cancer risk. 
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